Latest tumor Stories

A new approach mimicking the body's natural defenses could help treat a therapy-resistant breast cancer Cancer drugs of the new, molecular generation destroy malignant breast tumors in a targeted manner: They block characteristic molecules on tumor cells - receptors for the hormones estrogen or progesterone, or a co-receptor, called HER2, that binds to many growth factors. But about one in every six breast tumors has none of these receptors. Such cancers, called triple-negative, are...

PHILADELPHIA and REHOVOT, Israel, Feb. 7, 2013 /PRNewswire/ -- Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, "Predicting progression of bladder...

Researchers have identified two molecules that could potentially serve as biomarkers in predicting brain metastases in patients with breast cancer, according to data published in Cancer Research, a publication of the American Association for Cancer Research. Currently, most deaths from breast cancer are a result of metastatic disease. New research shows that cancer stem-like cells — commonly defined as cells within a tumor with the capacity to initiate a new tumor, proliferate rapidly,...

MADISON, Wis., Jan. 31, 2013 /PRNewswire/ -- Novelos Therapeutics, Inc. (OTCQX: NVLT), a pharmaceutical company developing novel drugs for the treatment and diagnosis of cancer, today announced that an oral presentation on research conducted by Novelos and its collaborators is being made by Dr. Christopher Pazoles at the EMIT: Targeted Radiotherapy international conference taking place January 29 to 31, in Washington, D.C. This presentation by invitation from EMIT describes the...

Patients with early stage breast cancer who were treated with lumpectomy plus radiation may have a better chance of survival compared with those who underwent mastectomy, according to Duke Medicine research. The study, which appears online Jan. 28, 2013, in the journal Cancer, raises new questions as to the comparative effectiveness of breast-conserving therapies such as lumpectomy, where only the tumor and surrounding tissue is surgically removed. “Our findings are observational but...

The spread of breast cancer to distant organs within the body, an event that often leads to death, appears in many cases to involve the loss of a key protein, according to UC San Francisco researchers, whose new discoveries point to possible targets for therapy. In the January 27, 2013 online edition of Nature Cell Biology, UCSF scientists describe for the first time how the protein, known as GATA3 — which is abnormal or absent in many cases of human breast cancer — normally acts...

IRVING, Texas, Jan. 28, 2013 /PRNewswire/ -- Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today the commercial availability of mutational analysis by Next-Generation Sequencing (NGS), which will replace its former mutational analysis platform. NGS joins an extensive collection of tumor profiling technologies currently employed by Caris Molecular Intelligence(TM) Service (MI Profile(TM)), including...

Universitat Autonoma de Barcelona A team of researchers led by the UAB has found the first ancient remains of a calcified ovarian teratoma, in the pelvis of the skeleton of a woman from the Roman era. The find confirms the presence in antiquity of this type of tumor - formed by the remains of tissues or organs, which are difficult to locate during the examination of ancient remains. Inside the small round mass, four teeth and a small piece of bone were found. Teratomas are usually...

New method is first to predict brain cancer outcome and quickly show if therapy is effective The critical question shortly after a brain cancer patient starts treatment: how well is it working? But there hasn't been a good way to gauge that. Now Northwestern Medicine researchers have developed a new method -- similar to forecasting storms with computer models -- to predict an individual patient's brain tumor growth. This growth forecast will enable physicians to rapidly identify how...

PALO ALTO, Calif., Jan. 24, 2013 /PRNewswire/ -- Varian Medical Systems (NYSE: VAR) has received FDA 510(k) clearance for the company's Edge(TM) radiosurgery suite, a new dedicated system for performing advanced radiosurgery using innovative real-time tumor tracking and motion management technologies. "The Edge suite represents a new paradigm in radiosurgery, offering clinicians a system that combines Varian's world-class technologies in an end-to-end solution for planning and...